ClinicalTrials.gov Identifier: NCT
|
|
- Bruno Carr
- 5 years ago
- Views:
Transcription
1 Efficcy of Drtumumb, Lenlidomide, nd Dexmethsone Versus Lenlidomide nd Dexmethsone in Relpsed or Refrctory Multiple Myelom Ptients With to 3 Prior Lines of Therpy: Updted Anlysis of POLLUX Sd Z. Usmni, Meletios A. Dimopoulos, 2 Andrew Belch, 3 Drrell White, 4 Lotfi Benboubker, 5 Gordon Cook, Merv Leib, 7 Jmes Morton, 8 P. Joy Ho, 9 Kihyun Kim, Noki Tkezko, Nushmi Z. Khokhr, 2 Mry Guckert, 2 Kid Wu, 2 Xing Qin, 2 Tineke Csneuf, 3 Christopher Chiu, 2 A. Kte Ssser, 2 Jesus Sn-Miguel 4 Levine Cncer Institute/Crolins HelthCre System, Chrlotte, NC, USA; 2 Ntionl nd Kpodistrin University of Athens, Athens, Greece; 3 Deprtment of Oncology, University of Albert Cross Cncer Institute, Edmonton, Albert, Cnd; 4 QEII Helth Sciences Center, Dlhousie University, Hlifx, Nov Scoti, Cnd; 5 Service d Hémtologie et Thérpie Cellulire, Hôpitl Bretonneu, Centre Hospitlier Régionl Universitire (CHRU), Tours, Frnce; St Jmes's Institute of Oncology, Leeds Teching Hospitls NHS Trust nd University of Leeds, Leeds, UK; 7 Sheb Medicl Center, Tel Hshomer, Rmt Gn, Isrel; 8 Icon Cncer Cre, South Brisbne, QLD, Austrli; 9 Institute of Hemtology, Royl Prince Alfred Hospitl, Cmperdown, NSW, Austrli; Deprtment of Medicine, Smsung Medicl Center, Sungkyunkwn University School of Medicine, Seoul, South Kore; Deprtment of Hemtology, Ntionl Hospitl Orgniztion Disster Medicl Center of Jpn, Tchikw, Jpn; 2 Jnssen Reserch & Development, LLC, Spring House, PA, USA; 3 Jnssen Reserch & Development, Beerse, Belgium; 4 Clínic Universidd de Nvrr-CIMA, IDISNA, Pmplon, Spin. CliniclTrils.gov Identifier: NCT279
2 Bckground Drtumumb Humn monoclonl ntibody trgeting CD38 Direct on-tumor nd immunomodultory MoA -5 Approved As monotherpy for hevily pretreted RRMM by the FDA, EMA, Helth Cnd, Mexico, nd Singpore Combo with stndrd of cre regimens for RRMM fter prior therpy (POLLUX nd CASTOR) by the FDA Erly studies demonstrted efficcy of drtumumb Rpid, deep, nd durble responses Well tolerted with mngeble dverse events MoA, mechnism of ction; RRMM, relpsed or refrctory multiple myelom ; FDA, Food nd Drug Administrtion; EMA, Europen Medicines Agency; CDC, complement-medited cytotoxicity; ADCC, ntibody-dependent cell-medited cytotoxicity; ADCP, ntibody-dependent cellulr phgocytosis.. Lmmerts vn Bueren J, et l. Blood. 24;24. Abstrct Overdijk MB, et l. MAbs. 25;7(2): Overdijk MB, et l. J Immunol. 2;97(3): Krejcik J, et l. Blood. 2;28(3): de Weers M, et l. J Immunol. 2;8(3):
3 Study Design Multicenter, rndomized (:), open-lbel, ctive-controlled, phse 3 study Key eligibility criteri RRMM prior line of therpy Prior lenlidomide exposure, but not refrctory Cretinine clernce 3 ml/min Strtifiction fctors No. of prior lines of therpy ISS stge t study entry Prior lenlidomide R A N D O M I Z E : (n = 28) Drtumumb mg/kg IV Qw in Cycles to 2, q2w in Cycles 3 to, then q4w until PD R 25 mg PO Dys to 2 of ech cycle until PD d 4 mg PO 4 mg weekly until PD (n = 283) R 25 mg PO Dys to 2 of ech cycle until PD d 4 mg PO 4 mg weekly until PD Cycles: 28 dys Pre-mediction for the tretment group consisted of dexmethsone 2 mg, cetminophen, nd n ntihistmine Primry endpoint PFS Secondry endpoints TTP OS ORR, VGPR, CR MRD Time to response Durtion of response Sttisticl nlyses Primry nlysis: ~77 PFS events ISS, interntionl stging system;, drtumumb/lenlidomide/dexmethsone; IV, intrvenous; qw, weekly; q2w, every 2 weeks; q4w, every 4 weeks; PD, progressive disese; R, lenlidomide; PO, orl; d, dexmethsone;, lenlidomide/dexmethsone; PFS, progression-free survivl; TTP, time to progression; OS, overll survivl; ORR, overll response rte; VGPR, very good prtil response; CR, complete response; MRD, miniml residul disese. On drtumumb dosing dys, dexmethsone 2 mg ws dministered s pre-mediction on Dy nd Dy 2. 3
4 Chrcteristic Age, y Medin (rnge) 75, % ISS stge, % I II III Medin (rnge) time from dignosis, y Cretinine clernce (ml/min), % N >3- > Cytogenetic profile, (%) b N Stndrd risk High risk Bseline Demogrphic nd Clinicl Chrcteristics (n = 28) 5 (34-89) (.4-27.) (n = 283) 5 (42-87) (.4-2.7) Chrcteristic Prior lines of therpy, % Medin (rnge) 2 3 >3-3 c (n = 28) (-) (n = 283) (-8) Prior ASCT, % 3 4 Prior PI, % Prior bortezomib, % Prior IMiD, % Prior lenlidomide, % Prior PI + IMiD, % Refrctory to bortezomib, % 2 2 Refrctory to lst line of therpy, % ASCT, utologous stem cell trnsplnttion; PI, protesome inhibitor; IMiD, immunomodultory drug. ISS stging is derived bsed on the combintion of serum β2-microglobulin nd lbumin. b Centrl next-genertion sequencing. High-risk ptients hd ny of t(4;4), t(4;), or del7p. Stndrd-risk ptients hd n bsence of high-risk bnormlities. c Explortory. 4
5 % surviving without progression No. t risk HR, hzrd rtio; CI, confidence intervl; scr, stringent complete response; PR, prtil response. Note: PFS = ITT popultion; ORR = response-evluble popultion. Kpln-Meier estimte; b P <. for vs. Updted Efficcy HR:.37 (95% CI,.28-.5; P <.) Months month PFS % 49% Medin: not reched 5 5 Medin: 7.5 months ORR, % CR: 4% b Medin (rnge) follow-up: 7.3 (-24.5) months ORR = 93% P <. VGPR: 78% b ORR = 7% (n = 28) (n = 27) Responses continue to deepen in the group with longer follow-up CR: 2% VGPR: 45% scr CR VGPR PR 5
6 MRD-negtive Rte * * * 3.X 4.4X 4.8X * P <.. MRD-negtive rte, % Sensitivity threshold 4 5 MRD-negtive rtes were >3-fold higher t ll thresholds Intent-to-tret popultion. P vlues re clculted using likelihood-rtio chi-squre test.
7 PFS: MRD Sttus ( 5 ) 8 MRD negtive (n = ) MRD negtive (n = 7) % progression-free nd live 4 MRD positive (n = 25) MRD positive (n = 27) 2 No. t risk MRD negtive MRD negtive MRD positive MRD positive Months MRD negtivity is ssocited with better outcomes Intent to tret popultion. 7
8 Time From Lst Line of Therpy to Study Tretment of > or 2 Months >2 Months 8-month PFS 2 Months 8-month PFS 83% % surviving without progression % % surviving without progression Medin:.3 months 7% 37% HR:.37 (95% CI:.23-.; P <.) No. t risk Months >2 > HR:.38 (95% CI:.2-.55; P <.) Months is superior to regrdless of time since lst therpy Kpln-Meier estimte. b Response-evluble popultion. 8
9 Refrctory to Lst Line of Therpy 8-month PFS 9 ORR = 87% b P =. % surviving without progression No. t risk Medin:.3 months HR:.47 (95% CI:.29-.7; P =.5) 5% 3% Months ORR, % CR: 47% c (n = 78) CR: 5% VGPR: 73% c ORR = 4% b 9 3 (n = 73) scr CR VGPR PR VGPR: 34% benefits ptients refrctory to lst line of therpy Kpln-Meier estimte. b Response-evluble popultion. c P <. for vs. 9
10 PFS: Cytogenetic Risk in All Evluble Ptients Comprble results in to 3 prior lines popultion % surviving without progression No. t risk std risk std risk high risk high risk Months stndrd risk high risk stndrd risk high risk High risk Stndrd risk Medin PFS, mo HR (95% CI) P vlue ORR, % P vlue n = 28 n = 33 n = 3 NR 7..3 (.8-.49) <. n = 37 Medin PFS, mo NR.2 HR (95% CI) P vlue.44 (.9-.3).475 n = 27 n = 3 ORR, % 85 7 P vlue NS n = 32 n = improves outcomes regrdless of cytogenetic risk NR, not reched; NS, not significnt. ITT/Biomrker risk evluble nlysis set. High-risk ptients hd ny of t(4;4), t(4;), or del7p. Stndrd-risk ptients hd n bsence of high-risk bnormlities.
11 OS % surviving ptients 8 4 OS events 4 (4%) in 5 (2%) in 2 HR:.3 (95% CI: ) No. t risk Months Curves re beginning to seprte, but OS dt re immture Intent-to-tret popultion. Medin OS ws not reched; results did not cross the prespecified stopping boundry.
12 Summry of Efficcy Results: to 3 Prior Lines Subgroup PFS Medin, mo HR (95% CI) ORR, % CR, % VGPR, % MRD-negtive rtes, % 4 5 Time from lst line of tx to study tx: >2 months Medin, mo PFS HR (95% CI) ORR, % Time from lst line of tx to study tx: 2 months Medin, mo PFS HR (95% CI) ORR, % Refrctory to lst line of therpy Medin, mo PFS HR (95% CI) ORR, % NR.3 (.2-.49) NR.38 (.23-.3) 94 b NR.35 ( ) 9 NR.45 ( ) b 89 b NR OS HR (95% CI).9 (.4-.5) NR, not reched; tx, tretment. P <. for vs. b P <. for vs. 2
13 Hemtologic, % Most Common AEs (All Ptients): Updted Anlysis Neutropeni Febrile neutropeni (n = 283) (n = 28) All grde Grde 3/4 All grde Grde 3/4 25% 5% 25% 5% Anemi Thrombocytopeni Lymphopeni Nonhemtologic, % Dirrhe Ftigue Upper respirtory trct infection Cough 3 3 Constiption Muscle spsms Nsophryngitis 2 7 Nuse 25.4 Pneumoni No new sfety signls reported Common tretment-emergent AEs listed re either 25% ll grde OR 5% grde 3/4. 3
14 Conclusions significntly improved outcomes for ptients with myelom 3% reduction in risk of progression or deth for versus Similr findings observed cross ll nlyses in the to 3 prior lines popultion More ptients chieve deeper responses including MRD negtivity with is superior to regrdless of time since lst therpy, refrctoriness to lst line of therpy, or cytogenetic risk Sfety profile remins unchnged These dt support the use of for ptients who received prior therpy regrdless of risk sttus or refrctoriness to prior tretment 4
15 Acknowledgments Ptients who prticipted in this study Investigtors Dt nd sfety monitoring committee Stff members involved in dt collection nd nlyses Dvid Soong nd Christopher Vels 8 countries This study ws funded by Jnssen Reserch & Development, LLC Medicl writing nd editoril support were provided by Json Jung, PhD, of MedErgy, nd were funded by Jnssen Globl Services, LLC 5
ClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationCheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More informationEfficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationClínica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain. ClinicalTrials.gov Identifiers: NCT and NCT
Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated With Daratumumab in Combination With Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More informationEfficacy of Sonidegib in Patients With Metastatic BCC (mbcc)
AAD 216 eposter 3368 Efficcy of Sonidegib in Ptients With Metsttic BCC (mbcc) Colin Morton, 1 Michel Migden, 2 Tingting Yi, 3 Mnish Mone, 3 Dlil Sellmi, 3 Reinhrd Dummer 4 1 Stirling Community Hospitl,
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationClinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess
More informationIMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC
IMpower133: Primry PFS, OS, nd sfety in Ph1/3 study of 1L tezolizumb + crbopltin + etoposide in extensive-stge SCLC S. V. Liu, 1 A. S. Mnsfield, 2 A. Szczesn, 3 L. Hvel, 4 M. Krzkowski, 5 M. J. Hochmir,
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationDaratumumab: Mechanism of Action
An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (D) Versus Lenalidomide and Dexamethasone () in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX* Meletios
More informationCheckMate-142 Study Design
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Thierry André, 1 Sr
More informationA review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital
MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground
More informationSupplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More informationThe RUTHERFORD-2 trial in heterozygous FH: Results and implications
The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationkey words: bortezomib, multiple myeloma, retrospective analysis, treatment outcomes, subcutaneous, intravenous
reserch report Effect of Route of Bortezomib Administrtion on Tretment Outcomes in Previously Untreted Ptients with Multiple Myelom: A Retrospective Anlysis from US Community Oncology Prctices Robert M
More informationAbstract. Background. Aim. Patients and Methods. Patients. Study Design
Impct of the Use of Drugs nd Substitution Tretments on the Antivirl Tretment of Chronic Heptitis C: Anlysis of Complince, Virologicl Response nd Qulity of Life (CHEOBS). Melin, 1 J.-. Lng, D. Ouzn, 3 M.
More informationMEDALIST Trial Background and Rationale
The MEDALIST Tril: Results of Phse 3, Rndomized, Double-Blind, Plcebo-Controlled Study of to Tret Ptients With Very Low-, Low-, or Intermedite-Risk Myelodysplstic Syndromes (MDS) Associted Anemi With Ring
More informationSponsor / Company: Sanofi Drug substance(s): AVE0005 (aflibercept)
These results re supplied for informtionl purposes only. Prescribing decisions should be mde bsed on the pproved pckge insert in the country of prescription. Sponsor / Compny: Snofi Drug substnce(s): AVE0005
More informationManagement of Relapsed/Refractory Follicular Lymphoma
April 2018 Volume 16, Issue 4, Supplement 10 Mngement of Relpsed/Refrctory Folliculr Lymphom n How I Tret Relpsed/Refrctory Folliculr Lymphom: An Expert Perspective n Highlights from: The 2017 Americn
More informationReference Slide Deck. Abstract 553 Abstract 554 Abstract 560
Clinicl Spotlight Immunotherpy Advnces for Colorectl Crcinom in 2018: Newly Relesed Dt From the Gstrointestinl Cncers Symposium in Sn Frncisco Reference Slide Deck Abstrct 553 Abstrct 554 Abstrct 560 Mismtch
More informationClinicalTrials.gov Identifier: NCT
Subcutaneous Delivery of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): PAVO, an Open-label, Multicenter, Dose Escalation Phase 1b Study Ajai Chari, 1 Hareth Nahi, 2 Maria-Victoria
More informationOriginal Article. Breast Care 2016;11: DOI: /
Originl Article Brest Cre 2016;11:323 327 DOI: 10.1159/000452079 Published online: October 24, 2016 Neodjuvnt Chemotherpy with Docetxel, Crbopltin nd Weekly Trstuzumb Is Active in HER2-Positive Erly Brest
More informationSafety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Sfety of Ocrelizumb in Multiple Sclerosis: Updted Anlysis in Ptients With Relpsing nd Primry Progressive Multiple Sclerosis SL Huser, L Kppos, X Montlbn, H Koendgen, C Chognot, C Li, C Mrcillt, A Prdhn,
More informationClinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer
Clinicl Evidence for Second- nd Third-Line Tretment Options in Advnced Non-Smll Cell Lung Cncer Filippo de Mrinis, Frncesco Grossi b Thorcic Oncology Unit I, Deprtment of Lung Diseses, Sn Cmillo nd Forlnini
More informationR Martino 1, P Romero 1, M Subirá 1, M Bellido 1, A Altés 1, A Sureda 1, S Brunet 1, I Badell 2, J Cubells 2 and J Sierra 1
Bone Mrrow Trnsplnttion, (1999) 24, 283 287 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Comprison of the clssic Glucksberg criteri nd the IBMTR Severity
More informationDARA Monotherapy Studies
Usmani, SZ. Blood. 26. http://dx.doi.org/.82/blood-26-3-752. Lokhorst HM, et al. N Engl J Med. 25;373(3):27-29. Lonial S, et al. Lancet. 25. I DARA Monotherapy Studies Baseline Characteristics Median (range)
More informationSTUDY DESIGN. VMP 6-week cycles, total of 9 cycles. Figure 2. Alcyone study design. Countries housing study sites are shaded in gold.
TPS8608 A Randomized Open-label Study of Bortezomib, Melphalan, And Prednisone (VMP) Versus Daratumumab () Plus VMP in Patients With Previously Untreated Multiple Myeloma (MM) Who Are Ineligible for High-dose
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationResults. Table 1: Demographic and Baseline Characteristics, Open-Label Safety Population Prior Double-Blind OC/APAP ER (n=77)
Open-Lbel Extension of Rndomized, Double-Blind, Plcebo-Controlled, Phse 3 Study of the Sfety nd Anlgesic Efficcy of MNK-795 Oxycodone/Acetminophen Extended-Relese (OC/APAP ER) Tblets in n Acute Pin Model
More informationPresented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE
Seven-Yer Interim Results from the ESPRIT 10-Yer Postmrketing Surveillnce Registry of Adlimumb for Moderte to Severe Psorisis Frncisco Kerdel, 1 Aln Menter, 2 Jshin J. Wu, 3 Mreike Bereswill, 4 Dilek Arikn,
More informationOlanzapine for the prophylaxis and rescue of chemotherapyinduced nausea and vomiting (CINV): a retrospective study
Originl Article Olnzpine for the prophylxis nd rescue of chemotherpyinduced nuse nd vomiting (CINV): retrospective study Leonrd Chiu, Nichols Chiu, Ronld Chow, Liying Zhng, Mrk Psetk, Jordn Stinson, Brenne
More informationEsophageal carcinoma is the eighth most common cancer
ORIGINAL ARTICLE Tumor-Strom Rtio Is n Independent Predictor for Survivl in Esophgel Squmous Cell Crcinom Ki Wng, MD,* Wei M, MD,* Jinbo Wng, MD,* Ling Yu, MD, Xiomei Zhng, MD, Zhenbo Wng, MD, Bingxu Tn,
More informationCity of Hope, Duarte, CA, USA; 11 Columbia University Medical Center, New York, NY, USA. 1
Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination With Pomalidomide and Dexamethasone in Patients With 2 Lines of Prior Therapy and Refractory or Relapsed and Refractory Multiple Myeloma
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Powell County. Public Health and Safety Division
Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationAntiviral Therapy 2015; 20: (doi: /IMP2874)
Antivirl Therpy 25; 2:79 79 (doi:.385/imp2874) Originl rticle Single dose permivir for the tretment of cute sesonl influenz: integrted nlysis of efficcy nd sfety from two plcebo-controlled trils Richrd
More informationTR Spitzer 1, CJ Friedman 2, W Bushnell 2, SR Frankel 3, J Raschko 4. Summary:
(2000) 26, 203 210 2000 Mcmilln Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nture.com/bmt Double-blind, rndomized, prllel-group study on the efficcy nd sfety of orl grnisetron nd orl ondnsetron
More informationThe incidence of melanoma, the most serious
Efectiveness nd sfety of ipilimumb therpy in dvnced melnom: evidence from clinicl prctice sites in the US Kim A Mrgolin, MD, Ahmd Trhini, MD, PhD, b Sumti Ro, PhD, c Monic Ktyl, JD, MPH, d I-Fen Chng,
More informationClinical Study. Oncology 2006;71:32 39 DOI: /
Oncology Clinicl Study Oncology 2006;71:32 39 DOI: 10.1159/000100447 Received: My 29, 2006 Accepted fter revision: December 9, 2006 Published online: Mrch 5, 2007 Efficcy of Consolidtion High-Dose Chemotherpy
More informationCommunity. Profile Yellowstone County. Public Health and Safety Division
Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Lewis & Clark County. Public Health and Safety Division
Community Helth Profile 2015 Lewis & Clrk County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Missoula County. Public Health and Safety Division
Community Helth Profile 2015 Missoul County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Anaconda- Deer Lodge County. Public Health and Safety Division
Community Helth Profile 2015 Ancond- Deer Lodge County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12
More informationPRACTICE GUIDELINE SERIES
PRACTICE GUIDELINE SERIES 131 I Tositumom in lymphom M.C. Cheung MD,* J.A. McEchern MD,* A.E. Hynes,* R.M. Meyer MD,* K. Imrie md* nd the Memers of the Hemtology Disese Site Group # of Cncer Cre Ontrio
More informationCommunity. Profile Carter County. Public Health and Safety Division
Community Helth Profile 2015 Crter County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationAge related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer
MOLECULAR AND CLINICAL ONCOLOGY 9: 329-334, 2018 Age relted differences in prognosis nd prognostic fctors mong ptients with epithelil ovrin cncer KENJI YOSHIKAWA, TAKESHI FUKUDA, RYO UEMURA, HIROAKI MATSUBARA,
More informationPrognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic
Crcinogenesis, 2015, Vol. 36, No. 2, 243 248 doi:10.1093/crcin/bgu247 Advnce Access publiction December 18, 2014 Originl Mnuscript originl mnuscript Prognostic significnce of pretretment serum levels of
More informationLung cancer is the most common cause of cancer deaths in
Originl Article A Phse I/II Study of Bortezomib in Combintion with Pclitxel, Crbopltin, nd Concurrent Thorcic Rdition Therpy for Non Smll-Cell Lung Cncer North Centrl Cncer Tretment Group (NCCTG)-N0321
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationStart ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4
F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND
More informationImpact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors
Originl Article Impct of Positive Nodl Metstses in Ptients with Thymic Crcinom nd Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, nd Jennifer L. Sullivn, MD Introduction: Thymic crcinoms
More informationEmerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data
Emerging Options for Thromboprophylxis After Orthopedic Surgery: A Review of Clinicl Dt Bob L. Lobo, Phrm.D. In four rndomized, controlled studies of ptients undergoing orthopedic surgery, the ntithrombotic
More informationof comorbid conditions, interventions Diagnosis and treatment, treatment reduction of risk factors for CVD to slow disease progression,
Tble 5.1. NKF Clssifiction of Chronic Kidney Disese nd Clinicl Fetures Stge Description GFR (ml/ min/1.73 m 2 ) U.S. Prevlence, b # Affected (%) Clinicl Fetures Action Pln c At incresed risk for CKD >60
More informationY. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3
Greter remission rtes in ptients with erly versus long-stnding disese in biologic-nive rheumtoid rthritis ptients treted with btcept: post hoc nlysis of rndomised clinicl tril dt Y. Yzici 1, D. Moniz Reed
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationSupplementary Online Content
Supplementry Online Content Rieckmnn N, Kronish IM, Shpiro PA, Whng W, Dvidson KW. Serotonin reuptke inhibitor use, depression, nd long-term outcomes fter n cute coronry : prospective cohort study. JAMA
More informationCharacteristics of hip involvement in patients with ankylosing spondylitis in Korea
ORIGINAL ARTICLE Koren J Intern Med 2017;32:158-164 Chrcteristics of hip involvement in ptients with nkylosing spondylitis in Kore Hyemin Jeong, Yeong Hee Eun, In Young Kim, Hyungjin Kim, Jejoon Lee, Eun-Mi
More informationIn the treatment of cardiovascular disease (CVD), national
n report n Beyond LDL Cholesterol: The Role of Elevted Triglycerides nd Low HDL Cholesterol in Residul CVD Risk Remining After Sttin Therpy Peter Algon Jr, MD, FACC In the tretment of crdiovsculr disese
More informationOne of the most important biological mechanisms of
Brief Report Serum Thymidine Kinse 1 Activity in the Prognosis nd Monitoring of Chemotherpy in Lung Cncer Ptients: A Brief Report Benjmin Nismn, PhD,* Hovv Nechushtn, MD, PhD,* Him Birn, MD, Hds Gntz-Sorotsky,
More informationMetformin and breast cancer stage at diagnosis: a population-based study
ORIGINAL ARTICLE METFORMIN AND BREAST CANCER STAGE AT DIAGNOSIS, Leg et l. Metformin nd brest cncer stge t dignosis: popultion-bsed study I.C. Leg md msc,* K. Fung msc,* P.C. Austin phd, nd L.L. Lipscombe
More informationHigh-dose therapy and autologous stem cell rescue for patients with Hodgkin s disease in first relapse after chemotherapy: results from the EBMT
Bone Mrrow Trnsplnttion, (1997), 745 752 1997 Stockton Press All rights reserved 0268 3369/97 $12.00 High-dose therpy nd utologous stem cell rescue for ptients with Hodgkin s disese in first relpse fter
More informationOriginal Article. Diabetes Metab J 2011;35:26-33 doi: /dmj pissn eissn
Originl Article Dibetes Metb J 211;35:26-33 doi: 1.493/dmj.211.35.1.26 pissn 2233-679 eissn 2233-687 D I A B E T E S & M E T A B O L I S M J O U R N A L Comprison of the Efficcy of Glimepiride, Metformin,
More informationDOSAGE FORMS AND STRENGTHS HIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed disodium)
More informationRisks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria
Clinicl Prctice: Mini-Review Received: My 20, 2016 Accepted fter revision: December 14, 2016 Published online: Jnury 27, 2017 Risks for All-Cuse Mortlity: Strtified by Age, Estimted Glomerulr Filtrtion
More informationIncreased Relative Mortality in Women With Severe Oxygen-Dependent COPD
CHEST Originl Reserch Incresed Reltive Mortlity in Women With Severe Oxygen-Dependent COPD Mgnus Ekström, MD ; Krl A. Frnklin, MD, PhD ; nd Kerstin E. Ström, MD, PhD COPD Bckground: Although the incidence
More informationImmune-Mediated Adverse Reactions Management Guide
Immune-Medited Adverse Rections Mngement Guide INDICATIONS AND USAGE YERVOY (ipilimumb) is indicted for: Tretment of unresectble or metsttic melnom in dults nd peditric ptients (12 yers nd older) Adjuvnt
More informationOpioid Use and Survival at the End of Life: A Survey of a Hospice Population
532 Journl of Pin nd Symptom Mngement Vol. 32 No. 6 December 2006 NHPCO Originl Article Opioid Use nd Survivl t the End of Life: A Survey of Hospice Popultion Russell K. Portenoy, MD, Un Sibircev, BA,
More informationEffect on Glycemic, Blood Pressure, and Lipid Control according to Education Types
Originl Article http://dx.doi.org/10.4093/dmj.2011.35.6.580 pissn 2233-6079 eissn 2233-6087 D I A B E T E S & M E T A B O L I S M J O U R N A L Effect on Glycemic, Blood Pressure, nd Lipid Control ccording
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed for injection),
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 09/2017 FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use Gemzr sfely nd effectively. See full prescriing informtion for Gemzr. GEMZAR (gemcitine for injection),
More informationA Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation
ORIGINAL CONTRIBUTIONS 3 see relted editoril on pge x A Rndomized Phse III Clinicl Tril of Plecntide, Urogunylin Anlog, in Ptients With Chronic Idiopthic Constiption Philip B. Miner Jr, MD, Willim D. Koltun,
More informationMultiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D.
Multiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm Nearly 24, new cases diagnosed in the US per year and 11, worldwide
More informationInhaled Corticosteroid Is Associated With an Increased Risk of TB in Patients With COPD
CHEST Originl Reserch Inhled Corticosteroid Is Associted With n Incresed Risk of TB in Ptients With COPD Jung-Hyun Kim, MD ; Ji-Soo Prk, MD ; Kyung-Ho Kim, MD ; Hye-Cheol Jeong, MD ; Eun-Kyung Kim, MD
More informationMOLECULAR AND CLINICAL ONCOLOGY 5: , 2016
MOLECULAR AND CLINICAL ONCOLOGY 5: 429-436, 2016 Improvement of survivl with postmstectomy rdiotherpy in ptients with 1-3 positive xillry lymph nodes: A systemtic review nd met-nlysis of the current literture
More informationGemmis Injection 38 mg/ml
Gemmis Injection 8 mg/ml Gemcitbine (Gemcitbine HCl) is nucleoside nlogue tht exhibits nti-tumor ctivity. The empiricl formul for Gemcitbine HCl is C 9H 11F 2N O.HCl. It hs moleculr weight of 299.66. Gemcitbine
More informationTreatment of leukemia with partially matched related bone marrow transplantation
Bone Mrrow Trnsplnttion, (1997) 19, 421 427 1997 Stockton Press All rights reserved 268 3369/97 $12. Tretment of leukemi with prtilly mtched relted bone mrrow trnsplnttion RK Munn 1, PJ Henslee-Downey
More informationChilblains (pernio, perniosis) are cold-induced, painful or itching
Nifedipine vs Plcebo for Tretment of Chronic Chilblins: A Rndomized Controlled Tril Ibo H. Souwer, MD 1 Jcobus H. J. Bor, BSc (Mth) 2 Pul Smits, MD, PhD 3 Antoine L. M. Lgro-Jnssen, MD, PhD 1 1 Deprtment
More informationImpact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting
Impct of Phrmcist Intervention on Dibetes Ptients in n Ambultory Setting Julie Stding, PhrmD, CDE, Jmie Herrmnn, PhrmD, Ryn Wlters, MS, Chris Destche, PhrmD, nd Aln Chock, PhrmD Dibetes is the seventh-leding
More informationA PHASE IIA STUDY OF TISOTUMAB VEDOTIN (HUMAX -TF-ADC) IN PATIENTS WITH RELAPSED, RECURRENT AND/OR METASTATIC CERVICAL CANCER
A PHASE IIA STUDY OF TISOTUMAB VEDOTIN (HUMAX -TF-ADC) IN PATIENTS WITH RELAPSED, RECURRENT AND/OR METASTATIC CERVICAL CANCER Vergote I, Concin N, Den E, Lssen U, Drew Y, Mchiels JP, Nielsen D, Arkenu
More informationPNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationAnalysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia
284 Anlysis of lterntives for izing ptients to chieve glycemic control nd void ccompnying risks of hypoglycemi JIALIN GAO 1,2*, QIANYIN XIONG 1,2*, JUN MIAO 1*, YAO ZHANG 2,3, LIBING XIA 1, MEIQIN LU 1,
More informationAntiviral Therapy 2015; 20: (doi: /IMP2920)
Antivirl Therpy 2015; 20:397 405 (doi: 10.3851/IMP2920) Originl rticle Sfety, tolerbility nd phrmcokinetics of dorvirine, novel HIV non-nucleoside reverse trnscriptse inhibitor, fter single nd multiple
More informationPegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi s sarcoma
REVIEW Pegylted liposoml doxorubicin in the tretment of AIDS-relted Kposi s srcom Ashish Udhrin 1 Keith M Skubitz 2 Donld W Northfelt 3 1 Deprtment of Medicine, Myo Clinic Arizon, AZ, USA; 2 Division of
More informationOriginal Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:
Fridpur Med. Coll. J. 214;9(2):61-67 Originl Article Nebuliztion by Isotonic Mgnesium Sulphte Solution with Provide Erly nd Better Response s Compred to Conventionl Approch ( Plus Norml Sline) in Acute
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationSeasonal influenza vaccination programme country profile: Ireland
Sesonl influenz vccintion progrmme country profile: Irelnd 2012 13 Seson Bckground informtion Influenz immunistion policy nd generl fcts bout Irelnd Volume indices of GDP per cpit in 2011 nd 2013 (EU-
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. doi: /ajg.2012.
A 12-Week, Rndomized, Controlled Tril with 4-Week Rndomized Withdrwl Period to Evlute the Efficcy nd Sfety of Linclotide in Irritble Bowel Syndrome with Constiption The Hrvrd community hs mde this rticle
More informationComparative Safety of Filgrastim versus Sargramostim in Patients Receiving Myelosuppressive Chemotherapy
Comprtive Sfety of Filgrstim versus Srgrmostim in Ptients Receiving Myelosuppressive Chemotherpy Gry Milkovich, B.S., Ronld J. Moleski, Phrm.D., John F. Reitn, Phrm.D., Dvid M. Dunning, M.D., Gene A. Gibson,
More informationPatients with cancer are at an increased
Risk of Cncer-Associted Thrombosis nd Bleeding in Veterns With Mlignncy Who Are Receiving Direct Orl Anticogulnts Mtthew Stnkowicz, PhrmD; Megn Bnszynski, PhrmD, BCOP; nd Russell Crwford, BPhrm, BCOP The
More information